Share
New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both. The study (the SURPASS-PEDS trial), led...
Share
Omodamola Aje, MD, has built a social media platform to provide women with the tools they need to ask their doctors informed questions and help guide decisions in their treatment, from menopause to hypothyroidism. Aje is using her platform to not only help build a sense of community, but to cut through the rampant misinformation...
Share
A recently published Scientific Statement sheds light on new and improved treatment options for type 1 diabetes. Endocrine News speaks with first author Aaron W. Michels, MD, about the Statement’s implications and why this is an exciting time in type 1 diabetes research. In July, the Endocrine Society published a Scientific Statement that highlights potential...
Share
The JCEM Case Reports Clinical Pearls session at ENDO 2025 featured three presentations of rare challenging endocrine cases that could answer questions for endocrinologists who could be treating patients with similar symptoms, possibly triggering further investigations that might lead to optimal outcomes. The audience for the third-annual JCEM Case Reports Clinical Pearls session at ENDO...
Share
From the pages of the Journal of the Endocrine Society, Endocrine News talks with Alan Rogol, MD, PhD, about the rarest of rare cases that involved growth hormone, Creutzfeldt-Jakob disease, and Alzheimer disease in a tale through time that involves rats, cadavers, and how one treatment evolved through scientific refinement. Has there ever been a...
Share
A recent clinical trial reveals encouraging news for a Cushing’s disease treatment A poster from ENDO 2025 showed that osilodrostat provides sustained clinical benefits in Cushing’s patients who experienced positive outcomes by the end of the treatment period. Richard Auchus, MD, PhD, discusses how the data reinforces the drug’s use, which was well-tolerated for extended...
Share
The U.S. Food and Drug Administration (FDA) recently granted a New Drug Application (NDA) for a hydrocortisone oral solution Eton Pharmaceuticals, Inc. is marketing as KHINDIVI™ — a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. KHINDIVI is the only FDA-approved oral solution formulation of hydrocortisone. It comes in a 1mg/ml...
Share
ENDO 2025 mines endocrine breakthroughs and breakouts in San Francisco When the biggest endocrinology conference in the world happens, professionals from around the world take notice! Over 7,000 endocrinologists hit the jackpot in San Francisco the second week in July for ENDO 2025 where there were more than just a few “eureka moments! People have...
